Gene Therapy Deals, M&A, and Venture Funding

by | Jun 20, 2019

Gene therapy deals, R&D partnerships, and acquisitions have been showing annual gains through 2018 and are on track to keep up the record in 2019. The recent approval of Novartis’ Zolgensma gene therapy for spinal muscular atrophy (SMA) was a good chance to look at the business development behind what are now looking like high-priced treatments. Data from the DealForma database and an analysis were prepared for a story published in Endpoints News.

We covered dealmaking, venture funding, M&A, and academic partnerships specifically looking at R&D for gene therapies and related vector technologies. We did not include gene editing in this focused analysis, nor recombinant DNA/RNA, cell therapies, or biologics.

This gave us an initial set of 256 academic partnerships, M&A, and corporate biopharma deals form January 2008 to June 14, 2019 among the broader set of 16,000+ deals. Add to that the 120 venture rounds in gene therapy focused biotech companies since 2010. Highlights below: 

Interesting Takeaways
  • 114 Corporate R&D deals; Over $1 billion in upfront cash and equity; $18 billion in deal value
  • 27 Acquisitions; $18 billion up front; $20 billion in total value
  • 115 University/foundation partnerships, grants, spin-offs; $100 million in upfront cash; $300 million in total value, plus $2 billion in total value for the 2016 Biogen/Upenn partnership
  • 120 Venture rounds from Seed through Series A and beyond up to IPO
  • $5 billion raised since 2010 with half of that in the last 18 months
  • Over $3 billion to companies with only a platform or preclinical therapy
DealForma Datasets
  • Biopharma Deals – R&D and commercialization deals for gene therapy and related vector technology platforms (adeno-associated viral (AAV) vectors, lentiviral vectors), preclinical and later compounds (Phase I, Phase II, Phase III, and Approved). A full list of criteria is available in the DealForma platform.
  • Mergers & Acquisitions – Active and completed M&A deals for gene therapy and vector companies. Excludes terminated deals.
  • Academic Research Partnerships and Grants – Gene therapy patent licenses, research grant programs, and sponsored research programs.
  • Venture Funding – Seed and Series A through F and beyond (pre-IPO) venture funding of gene therapy and vector-focused companies. Excludes loans and debt financing.

Story Published in Endpoints News: Read the full story with all of the charts

Run your own analysis with your DealForma access.

Schedule a Demo to See it in Action

Want data for your analysis? Want us to do it? Subscribers get both.

Schedule your demo of the DealForma database to see how we help you get better reports done faster.

28,664

Deal Profiles

18,893

Funding Rounds

32,123

Company Profiles

22,077

Product Profiles

119K+

Clinical Trials

3,967

Business Developers

Specifically for Biotech, Pharma, Device, and Diagnostics

More Research by DealForma

November 2021 Top Biopharma Deal: Sanofi – Owkin artificial intelligence and federated learning platform to advance Sanofi’s oncology pipeline

November 2021 Top Biopharma Deal: Sanofi – Owkin artificial intelligence and federated learning platform to advance Sanofi’s oncology pipeline

The top deal upfront for November 2021 was the Owkin – Sanofi artificial intelligence and federated learning platform research partnership to advance Sanofi’s oncology pipeline. Owkin will receive a $180M upfront equity investment, $90M in R&D funding over 3 years, and is eligible for additional undisclosed R&D milestones.

read more
October 2021 Top Biopharma Deal: Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies

October 2021 Top Biopharma Deal: Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies

The top deal upfront for October 2021 was the Xencor – Janssen deal for plamotamab and XmAb bispecific antibodies and new XmAb B-cell targeting bispecific antibodies for CD20-expressing hematologic malignancies. Xencor will receive $100M in upfront cash, $25M in an upfront equity investment, and is eligible for up to $1.18B in dev., reg., and sales milestones, plus tiered mid-teens to low-twenties royalties.

read more
September 2021 Top Biopharma Deal: REGENXBIO – AbbVie for RBX-314 for wet AMD, diabetic retinopathy

September 2021 Top Biopharma Deal: REGENXBIO – AbbVie for RBX-314 for wet AMD, diabetic retinopathy

The top deal upfront for September 2021 was the REGENXBIO – AbbVie deal for RGX-314 for wet AMD, diabetic retinopathy, and other chronic retinal diseases. REGENXBIO will receive $370M up front and is eligible for up to $1.38B in milestones, plus tiered royalties on net sales of RGX-314 outside the US and 50% of profits in the US.

read more
Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

CRISPR Therapeutics and Vertex Pharmaceuticals amended their 2015 deal to develop and commercialize gene editing therapies. This expansion is for Phase I/II CTX001 for severe sickle cell diseases and transfusion-dependent beta-thalassemia. CRISPR will receive $900M up front, up to $200M in milestones upon the first regulatory approval, and a cost/profit split of 40%.

read more
Top Biopharma Deal March 2021: Debiopharm – Merck KGaA for Xevinapant for head and neck cancer

Top Biopharma Deal March 2021: Debiopharm – Merck KGaA for Xevinapant for head and neck cancer

Debiopharm granted Merck exclusive, worldwide rights to develop and commercialize Xevinapant in Phase III for advanced squamous cell carcinoma of the head and neck. Debiopharm will receive EUR188M ($227M) up front and is eligible for up to EUR710M ($856M) in milestones, plus royalties. This was the largest upfront cash and equity for a partnership signed in March 2021.

read more
Biotech and Pharma Deals in 2020

Biotech and Pharma Deals in 2020

Biotech and pharma deals in 2020 soared to an all-time high of 1,154 signed deals with $146.3 billion in total value, defying expectations that the global Covid-19 pandemic would hamper dealmaking. Global healthcare and life sciences R&D partnership activity was up 23 percent over 2019 and total deal values rose 31 percent from the previous year, driven in part by advances in technological and molecular understandings of disease pathways, and a drive toward targeted precision medicines.

read more

You met on Zoom. Now it's Deal Time.

With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.